Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INCY

Incyte Corp

Mar 21 • 04:00PM ET

61.92

Dollar change +1.34
Percentage change 2.21	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO VB RSP VO SPY XBI IVV USMV VBK

Scroll to Statements

Index	S&P 500	P/E	228.32	EPS (ttm)	0.27	Insider Own	1.45%	Shs Outstand	193.43M	Perf Week	-8.75%
Market Cap	11.98B	Forward P/E	9.67	EPS next Y	6.40	Insider Trans	-2.02%	Shs Float	190.72M	Perf Month	-13.25%
Income	32.62M	PEG	2.37	EPS next Q	1.02	Inst Own	95.45%	Short Float	3.07%	Perf Quarter	-10.78%
Sales	4.24B	P/S	2.83	EPS this Y	417.00%	Inst Trans	0.02%	Short Ratio	3.53	Perf Half Y	-4.99%
Book/sh	17.82	P/B	3.47	EPS next Y	15.06%	ROA	0.53%	Short Interest	5.85M	Perf Year	6.15%
Cash/sh	11.15	P/C	5.55	EPS next 5Y	96.16%	ROE	0.76%	52W Range	50.35 - 83.95	Perf YTD	-10.35%
Dividend Est.	-	P/FCF	48.11	EPS past 5Y	-40.36%	ROI	0.93%	52W High	-26.24%	Beta	0.89
Dividend TTM	-	Quick Ratio	1.94	Sales past 5Y	14.56%	Gross Margin	91.09%	52W Low	22.98%	ATR (14)	2.53
Dividend Ex-Date	-	Current Ratio	1.97	EPS Y/Y TTM	-88.32%	Oper. Margin	1.89%	RSI (14)	31.26	Volatility	4.02% 3.33%
Employees	2617	Debt/Eq	0.02	Sales Y/Y TTM	14.76%	Profit Margin	0.77%	Recom	2.42	Target Price	74.94
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	14.62%	Payout	0.00%	Rel Volume	2.61	Prev Close	60.58
Sales Surprise	3.39%	EPS Surprise	-5.06%	Sales Q/Q	16.32%	Earnings	Feb 10 BMO	Avg Volume	1.65M	Price	61.92
SMA20	-9.43%	SMA50	-12.34%	SMA200	-8.65%	Trades		Volume	4,323,111	Change	2.21%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100
Aug-03-22	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Mar-22-25 06:46AM	What Moved Markets This Week (SeekingAlpha)
Mar-21-25 11:56AM	Why Incyte Stock Was Tanking This Week (Motley Fool)
09:01AM	1 Healthcare Stock on Our Watchlist and 2 to Brush Off (StockStory)
04:46AM	The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics (Zacks)
02:30AM	Incyte Had a Bad Week. Investors Are Used to It. (Barrons.com)
01:03PM	Loading…
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
12:45PM	Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More (Zacks)
Mar-19-25 08:06AM	Incyte price target lowered to $72 from $74 at Truist (TipRanks)
Mar-18-25 07:01PM	Analyst Report: Incyte Corporation (Morningstar Research)
08:05AM	Stoke CEO exits; Medicare drug price talks advance (BioPharma Dive)
05:32AM	Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-17-25 04:52PM	Incyte stock dives after drug trial disappoints investors (Yahoo Finance Video) -8.62%
04:32PM	S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision (Investopedia)
04:11PM	Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive' (Investor's Business Daily)
02:09PM	Oil pressures, Robinhood, Incyte: Market Minute (Yahoo Finance Video)
01:52PM	Loading…
01:52PM	Why Incyte (INCY) Stock Is Nosediving (StockStory)
01:11PM	Incyte stock hit 11% despite paediatric dermatology trials hitting target (Clinical Trials Arena)
12:00PM	Top Stock Movers Now: Intel, Netflix, Incyte, and More (Investopedia)
12:00PM	Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results (Investopedia)
11:21AM	Incyte Is Todays Worst S&P 500 Stock. Heres Why. (Barrons.com)
11:20AM	Nvidia, Netflix, Berkshire Hathaway, Baidu, Incyte, NCL, Affirm: Stocks to watch today (Quartz)
09:53AM	Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls (Benzinga)
09:16AM	Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' (Investor's Business Daily)
08:40AM	Nvidia, Berkshire Hathaway, Baidu, Lockheed Martin, Incyte, NCL: Stocks to watch today (Quartz)
07:00AM	Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa (Business Wire)
Mar-12-25 11:30AM	Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-11-25 08:48AM	Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss (Benzinga)
Mar-10-25 01:38PM	Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps (Benzinga)
Mar-08-25 01:00PM	Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study (PR Newswire)
09:01AM	Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting (Business Wire)
04:30PM	Loading…
Mar-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-25 02:31PM	Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-28-25 09:30AM	Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Feb-25-25 08:53AM	Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery (Insider Monkey)
Feb-21-25 07:20AM	Incyte and Genesis collaborate on small-molecule medicines (Pharmaceutical Technology)
Feb-20-25 08:00AM	Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration (Business Wire)
Feb-18-25 04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
03:00AM	Incyte Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
Feb-11-25 05:55PM	Analyst Report: Incyte Corporation (Morningstar Research)
02:04AM	Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook (GuruFocus.com)
Feb-10-25 11:28PM	Q4 2024 Incyte Corp Earnings Call (Thomson Reuters StreetEvents) -7.86%
05:27PM	S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update (Investopedia)
04:43PM	Incyte Reports 2024 Financial Results and Outlines 2025 Projections (GuruFocus.com)
02:56PM	Why Incyte (INCY) Shares Are Plunging Today (StockStory)
02:47PM	Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short (Investopedia)
10:38AM	Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches (Benzinga)
09:30AM	Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Incyte (INCY) Q4 Earnings Miss Estimates (Zacks)
07:30AM	Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4 (StockStory)
07:23AM	Incyte: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones (Business Wire)
Feb-09-25 08:02AM	Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow (StockStory)
Feb-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.86%
Feb-05-25 09:15AM	Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-03-25 10:00AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-21-25 08:00AM	Incyte to Report Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
Jan-15-25 05:34PM	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes (PR Newswire)
08:54AM	JP Morgan 2025: Incyte expects period of defining catalysts (Pharmaceutical Technology)
Jan-13-25 09:40AM	Has Incyte (INCY) Outpaced Other Medical Stocks This Year? (Zacks)
08:30AM	Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-08-25 06:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-20-24 07:20AM	Incyte price target raised to $70 from $68 at Wells Fargo (TipRanks)
Dec-17-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Dec-11-24 06:06PM	ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma (Clinical Trials Arena)
Dec-10-24 10:30AM	Incyte Late-Breaking Tafasitamab (Monjuvi) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Dec-09-24 04:46PM	Analyst Report: Incyte Corporation (Morningstar Research) -5.02%
Dec-07-24 07:30AM	Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (Business Wire)
Dec-06-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.02%
Nov-28-24 11:31AM	Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report? (Zacks)
Nov-26-24 04:10PM	Incyte Announces Updated Presentation Time for Upcoming Investor Conference (Business Wire)
Nov-25-24 10:09AM	Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting (Business Wire)
Nov-22-24 06:01AM	Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock (Insider Monkey)
Nov-20-24 04:31PM	Analyst Report: Incyte Corporation (Morningstar Research)
Nov-19-24 04:30PM	S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing (Investopedia) -8.33%
04:02PM	Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. (Investor's Business Daily)
12:41PM	Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study (Investopedia)
12:21PM	Incyte Is the S&P 500s Worst Performer Today. Whats Hitting the Stock. (Barrons.com)
12:18PM	Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges (Benzinga)
11:30AM	Incyte Faces Challenges but Remains Focused on Strategic Growth (GuruFocus.com)
06:13AM	Incyte sinks on setback for drugs acquired in $750M buyout (BioPharma Dive)
Nov-18-24 10:40PM	Analyst Report: Incyte Corporation (Morningstar Research)
04:30PM	Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs (Business Wire)
08:28AM	Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
Nov-16-24 10:06AM	Heres How Jakafis Patent Expiry Impacts Incyte Corporations (INCY) Growth Prospects (Insider Monkey)
Nov-15-24 07:05PM	Analyst Report: Incyte Corporation (Morningstar Research)
Nov-14-24 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Nov-07-24 07:22PM	Analyst Report: Incyte Corporation (Morningstar Research)
04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-24 06:02AM	Bank of America Turns Bullish on These 2 Lesser-Known Stocks (TipRanks)
Nov-05-24 04:32AM	Syndax agrees funding with Royalty Pharma for Niktimvo US sales (Pharmaceutical Technology)
Oct-30-24 04:37PM	Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock (Benzinga)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
03:03AM	Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:05AM	Q3 2024 Incyte Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-29-24 04:59PM	S&P 500 Gains and Losses Today: Ford Stock Falters as Earnings Miss the Mark (Investopedia) +12.04%
04:10PM	Incyte Breaks Out To 17-Month High As Jakafi Demand Surges (Investor's Business Daily)
12:23PM	Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted (GuruFocus.com)
12:07PM	Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura (Benzinga)
09:30AM	Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings (Zacks)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flannelly Barry P	EVP & General Manager US	Mar 14 '25	Sale	67.69	19,807	1,340,656	33,567	Mar 18 04:01 PM
BARRY FLANNELLY	Officer	Mar 14 '25	Proposed Sale	67.69	19,807	1,340,728		Mar 14 04:11 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Option Exercise	58.06	599	34,778	26,447	Mar 06 04:56 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Sale	69.99	599	41,924	25,848	Mar 06 04:56 PM
SHEILA DENTON	Officer	Mar 04 '25	Proposed Sale	69.99	599	41,924		Mar 04 05:12 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Option Exercise	58.06	9,574	555,866	39,917	Feb 28 06:34 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Sale	74.07	14,069	1,042,136	25,848	Feb 28 06:34 PM
SHEILA DENTON	Officer	Feb 26 '25	Proposed Sale	74.07	14,069	1,042,138		Feb 26 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 21 '25	Sale	72.69	12,352	897,867	66,967	Jan 22 04:05 PM
STEVEN STEIN	Officer	Jan 21 '25	Proposed Sale	72.69	12,352	897,906		Jan 21 04:03 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '24	Sale	70.64	650	45,916	23,962	Dec 17 12:37 PM
Tray Thomas	Principal Accounting Officer	Dec 16 '24	Sale	69.31	650	45,052	23,312	Dec 17 12:37 PM
THOMAS R TRAY	Officer	Dec 16 '24	Proposed Sale	69.31	650	45,052		Dec 16 04:04 PM
Iyengar Vijay K	EVP, GMAPPS	Nov 29 '24	Sale	75.38	6,043	455,544	30,658	Dec 03 12:52 PM
VIJAY IYENGAR	Officer	Nov 29 '24	Proposed Sale	75.39	6,043	455,555		Nov 29 01:28 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Option Exercise	70.03	3,680	257,719	61,722	Nov 08 12:48 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Sale	79.68	3,680	293,210	58,042	Nov 08 12:48 PM
BARRY FLANNELLY	Officer	Nov 06 '24	Proposed Sale	79.68	3,680	293,210		Nov 06 04:15 PM
Tray Thomas	Principal Accounting Officer	Sep 12 '24	Sale	62.94	572	36,002	24,825	Sep 16 01:25 PM
Tray Thomas	Principal Accounting Officer	Sep 13 '24	Sale	63.37	382	24,207	24,443	Sep 16 01:25 PM
Dickinson Jonathan Elliott	EVP, General Manager, Europe	Sep 12 '24	Sale	62.36	8,450	526,948	36,390	Sep 16 01:24 PM
THOMAS R TRAY	Officer	Sep 13 '24	Proposed Sale	63.37	382	24,207		Sep 13 04:06 PM
JONATHAN ELLIOTT DICKINSON	Officer	Sep 12 '24	Proposed Sale	62.36	8,450	526,930		Sep 12 04:17 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 12 '24	Sale	60.63	11,608	703,793	90,011	Aug 14 03:37 PM
STEVEN STEIN	Officer	Aug 12 '24	Proposed Sale	60.63	11,608	703,771		Aug 12 04:39 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 25 '24	Sale	70.00	15,571	1,089,970	36,701	Jul 29 03:50 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '24	Sale	64.19	1,306	83,832	58,042	Jul 17 12:24 PM
Flannelly Barry P	EVP & General Manager US	Jul 09 '24	Sale	60.00	8,148	488,880	50,534	Jul 11 12:35 PM
Flannelly Barry P	EVP & General Manager US	Jun 12 '24	Sale	60.00	19,164	1,149,840	66,377	Jun 14 12:17 PM
Tray Thomas	Principal Accounting Officer	Jun 06 '24	Sale	58.91	1,093	64,389	21,634	Jun 10 12:25 PM
BAKER BROS. ADVISORS LP	Director	May 07 '24	Option Exercise	49.01	30,000	1,470,300	33,462,981	May 09 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp

Upgrade your FINVIZ experience